Back

Right ventricular dysfunction and mortality in breast cancer patients treated with anthracyclines: a retrospective cohort study

11 December 2025 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology: what are the new imaging insights? Systolic and Diastolic Function EACVI Premium Access EACVI 2025 European Association of Cardiovascular Imaging (EACVI)

About the speaker

Photo
Doctor Novi Yanti Sari

Siloam Hospitals Group, Jakarta (Indonesia)

6 More presentations in this session

Presentation thumbnail
Under pressure: right ventricular and right atrial strain predict in-hospital death in cancer patients with pulmonary embolism
Doctor A. Vijiiac (Bucharest, RO)
Abstract Slides
Presentation thumbnail
Predictive value of global longitudinal strain (GLS) in breast cancer patients undergoing trastuzumab-based chemotherapy
Doctor V. Dimitrova (Sofia, BG)
Abstract Slides
Presentation thumbnail
Assessing cancer therapy-related cardiac dysfunction risk in non-Hodgkin lymphoma patients, the role of comprehensive echocardiographic monitoring
Doctor D. Bursacovschi (Chisinau, MD)
Abstract Slides
Presentation thumbnail
Risk prediction model for early left ventricular systolic dysfunction in breast cancer patients when the global longitudinal strain is not available
Doctor A. Stevanovic (Belgrade, RS)
Abstract Slides
Presentation thumbnail
Semaglutide preserves myocardial function in a murine model of sequential anthracycline trastuzumab induced early cardiotoxicity: insights from speckle tracking echocardiography
Doctor N. Maurea (Naples, IT)
Abstract Slides

Access the full session

Session thumbnail
Cardio-oncology: what are the new imaging insights?

The Event

Event poster

EACVI 2025

11 December - 13 December 2025
You may be interested in
thumbnail
Congress Presentation
Diastolic function and left atrial pressures
thumbnail
Congress Presentation
LV diastolic function: how to deal with challenges
thumbnail
Congress Presentation
Evaluation of diastolic function and LV filling pressures: limitations of current guidelines 

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources